In This Article:
Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution for improving the management of chronic obstructive pulmonary disease (COPD).
The collaboration will focus on testing the usage of the care acceleration solution, the Viz COPD module, which will utilise electronic health record (EHR) data and AI for progressing the identification and management of COPD patients who are at elevated risk.
COPD, a prevalent and progressive lung condition, causes restricted airflow and troubled breathing.
The module is set to assess EHR data through natural language processing, aligning with established clinical guidelines to screen and triage subjects, and highlighting those at elevated risk for further care and follow-up.
It is built upon the company’s current presence across more than 1,700 health systems and hospitals, engaging more than 60,000 healthcare providers to enhance care and diagnosis in various diseases areas, including respiratory conditions.
The partnership between the three parties is poised to increase patient impact, especially for those who would benefit significantly from enhanced care co-ordination.
Viz.ai co-founder and CEO Chris Mansi stated: “This collaboration with Sanofi and Regeneron is a major step forward in our mission to expand AI-driven care co-ordination across disease areas with critical unmet needs, such as COPD. Our approach aims to empower healthcare providers to deliver data-driven, guideline-directed care that meaningfully impacts patient outcomes.
“We look forward to collaborating with Sanofi and Regeneron to harness AI to accelerate advancements in disease management and improve patient access to care.”
Viz.ai leverages machine learning and AI algorithms to expedite the diagnosis and care process across numerous hospitals and health systems in Europe and the US.
Viz.ai One, an AI-powered intelligent care co-ordination solution, detects individuals with suspected diseases, supports critical decision-making and aids in improving the outcomes of patients.
Supported by real-world clinical evidence, the solution delivers substantial value to providers, patients, pharma and medical device manufacturers.
"Viz.ai, Sanofi and Regeneron to link for COPD management" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.